Thursday, 15 August 2013

Inflammatory bowel disease (IBD) is an immune-mediated disease in which the body’s own immune system attacks the parts of the digestive system of the human body. Such disease involves inflammation of lower gastrointestinal tract and causes irreversible damage to the bowel. Ulcerative colitis and Crohn’s disease are the two major forms of IBD; both having distinct pathologic and clinical characteristics. IBD is a difficult to manage medical condition with a higher morbidity rate and thus its diagnosis and management is of utmost importance.


The global inflammatory bowel disease market is categorized as follows:
Application
  • Therapeutic
  • Diagnostic
Diseased condition
  • Crohns disease
  • Ulcerative colitis
Product type
  • Aminosalicylates
  • Antibiotics
  • Corticosteroids
  • Biologic therapies (biological drugs)
  • Immunomodulators
Currently, the developed global markets of North America and Europe make up for the majority of the inflammatory bowel disease market in the world. Emerging markets of Asia mainly India, Russia and Japan as well as countries of Middle East and Latin America are also expected to show strong growth due to rising incidences of such diseases owing to increased industrialization, modernization of the population and drastic lifestyle changes.

One of the key factors driving the growth of this market is the increase in use of biological therapies such as monoclonal antibodies. However, difficulties involved in affording the expensive treatments of such diseases may pose challenge to growth of inflammatory bowel diseases market majorly in developing nations.

Some of the key players in this industry are Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Alcon, Inc., Baxter International, Inc., Johnson & Johnson, Sequella, Inc., Sanofi-Aventis LLC, Osiris Therapeutics, Inc., AstraZeneca PLC, Eisai Co. Ltd., Cephalon, Inc., Celltrion, Inc., Pfizer, Inc., Pluristem Therapeutics, Inc., Soligenix, Inc. and Ore Pharmaceuticals, Inc.


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Wednesday, 14 August 2013

Interventional radiology involves the use of minimally invasive procedures in the diagnosis (example: angiograms) and treatment (example: angioplasties) of various medical conditions. These procedures are performed with the aid of image guidance systems. Interventional radiology includes various processes such as biopsies, cancerous/non-cancerous tumor removal and intravascular procedures. Interventional radiology systems offer best image quality and high efficacy for various diagnostic and treatment procedures. 


The Society of Interventional Radiology (SIR) based in the U.S. is witnessing a steady growth in the memberships worldwide. At present, there are more than 4000 members worldwide. The major types of interventional radiological procedures in practice are angioplasty, venous access, biopsy, fibroid embolization, stents, arteriogram and embolization. Image-guided interventional radiology systems assist radiologists to conduct efficient and minimally invasive surgeries with the help of guide wires, catheters and stents.

The replacement of open surgeries with minimally invasive procedures is one of the key trends in medicine industry. The increasing popularity of minimally invasive procedures has spurred the demand for hybrid operating rooms incorporating interventional radiology systems. The market for interventional radiology systems is witnessing commendable growth due to their high efficacy, technological advances and wide application areas. 

Interventional radiology market can be segmented by product types, technological platforms, application areas and geographies. Various application areas of interventional radiology products comprise of neurology, cardiology, gastrointestinal and urology. The product segments comprise of guide wires, catheters and guiding catheters.

The increasing popularity of vascular closure, coronary stents and angioplasty balloons and other associated equipments ensure growth of the market in the near future. The major factors driving growth of the interventional radiology market are increasing incidence of chronic disorders, high acceptance of minimally invasive procedures, technological advances, changing lifestyle of the consumers inviting serious health conditions and high efficiency of the interventional cardiology systems. People aged 50 years and above form the major target patient population to avail the interventional radiology procedures. 

The approaching market saturation, economic fluctuations and less availability are the factors which might hinder the growth of the market. Abbott Laboratories, Boston Scientific Corporation, Cordis Corporation, Medtronic, Inc. and St. Jude Medical, Inc., are some of the key players in the interventional radiology market.


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Wednesday, 7 August 2013

Chronic Myeloid Leukemia (CML) is a type of blood cancer caused by uncontrolled growth of the cells in bone marrow. CML is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from CML show increased susceptibility to infections, thrombocytopenia, anemia and may also have enlarged spleen which causes pain on the left side. 


Incidence rate of CML is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for CML depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatments for CML include chemotherapy, stem cell transplants and biologic therapies. Drugs available in the market are tyrosine Kinase inhibitor. 

About 90% of the CML cases occur in the middle age and progresses with the aging. Therefore, CML drugs market is poised to grow with the rise in aging population and increasing incidences of CML. Drugs such as Gleevec (Imatinib Mesylate), Bosulif (Bosutinib), Sprycel (Dasatinib), Iclusig (Ponatinib Hydrochloride) and others are commercially available for the treatment of CML. These drugs have improved the survival rate of the patient by 92.5%. Gleevec was the first CML drug introduced in 2001, since then there has been a revolutionary change in the quality life of patient as compared to the former chemotherapy drugs.

One of the major risk factor associated with occurrence of CML is the exposure to ionizing radiations. For instance cases of CML were mainly indicated in the regions where people were exposed to atomic bombings (Hiroshima and Nagasaki). Recently in 2012, Ponatinib received FDA approval for the treatment of CML. Further, players in the market are adopting various growth strategies such as mergers and acquisitions, new product launches, innovative product pipeline to remain competitive. Some of the market players in this industry are Novartis Pharmaceuticals, Bristol-Myers Squibb, Ariad Pharmaceuticals, Inc, Pfizer and others. 

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  

This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030


Wednesday, 31 July 2013

Therapeutic vaccines function by triggering a body immune response against a disease. The global therapeutic vaccines market was valued at USD 292 million in 2011. The introduction of therapeutic vaccines has opened up new avenues in the field of chronic disease treatment and prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy drug to treat prostate cancer in men in 2010, which has encouraged rigorous research and development initiatives by pharmaceutical companies to develop novel vaccines for untapped disease segments. As a result of these initiatives, many more therapeutic vaccines are currently in the pipeline such as breast cancer vaccine, lung cancer vaccine; Alzheimer’s vaccine, malaria vaccine, and diabetes vaccine are expected to be introduced in the market during the period from 2012 to 2018.

Browse for full report: Therapeutic Vaccines Market 

The market is currently facing growth hindrances as R&D approaches, and regulatory and reimbursement policies are inconspicuous owing to the nascent nature of the market. However, regulatory bodies are working enthusiastically to lay out policies and growth strategies, due to the fact that it holds the potential to solve or curb chronic diseases, with no currently available treatments, such as HIV AIDS.

Four components hold imperative importance in designing a therapeutic vaccine:
  • Antigens: These are substances that evoke an immune response from the body and are responsible for the production of antibodies
  • Adjuvants: These are immunological agents that help in modifying the effects of a drug or vaccine. Companies are now engaged in designing new adjuvants that will help in enhancing the immunogenicity of an antigen
  • Cost effective production systems for vaccines
  • Designing innovative drug delivery devices to enhance vaccine efficacy 
The North American therapeutic vaccine market is expected to generate the maximum revenue in the global market during the forecasted period due to the presence of efficient R&D facilities and sophisticated medical infrastructures. The market is segmented into three major application segments namely oncology, infectious diseases and other chronic disorders. The therapeutic vaccine market with oncology applications market held the majority of the market share in 2011, as most of the research and development exercises are expected to be directed towards this segment during 2012 to 2018.

Merck and GSK have strong therapeutic vaccine product pipelines and are expected to perform better during 2012 to 2018 than their competitors who have fewer products in the pipeline. Some of the other key players of the market include Sanofi-Pasteur, Cytos Biotechnology AG, and Intellect Neurosciences.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.
Hepatitis is a medical condition characterized by inflammation of the liver which often leads to other complications such as jaundice, anorexia, liver failure and cirrhosis. Hepatitis is generally of two types- acute when it lasts for less than six months and chronic when it lasts for longer period. It can be caused by a group of viruses called as hepatitis viruses which include groups A, B, C, D, and E. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.

Browse for full report: Hepatitis Diagnostic Market

Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination. Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. No vaccine is yet available for prevention of hepatitis C.

Hepatitis A, B, C, D and E can be diagnosed by combinations of various specific tests containing enzymes, antibodies and antigens. These are: enzyme immunoassay (EIA), recombinant immunoblot assay (RIBA), transcription-mediated amplification (TMA) and polymerase chain reaction (PCR). The EIA technology is used for antibody as well as antigen detection whereas the other technologies are used to test DNA and RNA to check the presence of hepatitis viruses.

Hepatitis A and E are mainly caused by consumption of contaminated food or water. Hepatitis B, C and D occur as a result of contact with infected body fluids. Common modes of transmission and infection for these viruses include receipt of infected blood or blood products, invasive medical procedures using contaminated equipments. Hepatitis B can be transmitted from mother to baby at the time of birth and by sexual contact. Prevalence of hepatitis A, hepatitis B and hepatitis C in North American countries is 33%, 5% and 1.5% respectively. Thus, North America has registered the highest cases of hepatitis infections followed by Asia-Pacific and then Europe.

Some of the key players involved in the development of diagnostics for hepatitis are Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Tuesday, 30 July 2013

Lymphoma is a kind of blood cancer which occurs when B or T lymphocytes and leukocytes grow abnormally. In addition, it also occurs if these cells survive longer than their normal life cycle. Lymphoma generally occurs in lymph nodes, bone marrow, spleen, blood and other organs which form a part of the lymphatic system. The common symptoms of lymphoma are swelling of lymph nodes, fever, weight loss, night sweets, anorexia, itching, dyspnoea and fatigue. The common tests applied for the diagnosis of lymphoma are immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing and flow cytometry. The most common method to threat lymphoma is chemotherapy.

Browse for full report: Lymphoma Treatment Drugs Market

Since chemotherapy destroys the cancer cell by obstructing its division process, it acts as one of the key method for lymphoma treatment. These medicines travels throughout the body while medication. Various drugs are used for the treatment of lymphoma such as Adcertis (brentuximab), Arranon (nelarabine), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexamethasone Intensol (dexamethasone), Dexpak Taperpak (dexamethasone) and Folotyn (pralatrexate). Other drugs used include Prednicot (prednisone), Roferon-A (interferon alfa-2a), Solurex (dexamethasone), Leukeran (chlorambucil), Zema Pak (dexamethasone), Velcade (bortezomib), Sterapred DS (prednisone), Thioplex (thiotepa), Velban (vinblastine) and Trexall (methotrexate).

Rise in the incidence of lymphoma throughout the globe would boost the growth of lymphoma treatment drugs market. According to Leukemia and Lymphoma Society, in 2012, around 700,000 people were suffering from lymphoma in Canada alone. The government of various nations such as U.S. and Europe has amplified their funding for R&D on lymphoma treating drugs which would further augment the growth of this market. Moreover, they have started many programs for patient awareness about lymphoma and its treatments. Despite all these advantages, various side effects of chemotherapy would hamper the growth of this market. These side effects include hair loss, nausea, vomiting and fatigue. In addition, high cost of this treatment would also hamper the growth of this market. Moreover, few nations such as U.K are not providing reimbursement for every lymphoma treating drug which would hamper its growth in this region. Some of the major players in lymphoma treatment drugs market includes Abbott Laboratories, Eli Lilly, Bristol-Myers Squibb, Abiogen, Johnson & Johnson, Aeterna Zentaris among others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.
Anti-infective agents are drugs used for the purpose of killing and/or suppressing the infection causing organisms from invading the host organism by means of its replication or releasing variety of toxins in the host. Such infection causing micro-organisms include viruses, bacteria, fungi, viroids and macro parasites. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by host. 

Browse full report at: Anti-Infectives Market

The global market for anti-infectives is classified by product type as antifungal, antiviral and antibacterial depending on the type of organism they fight. Geographically, North America is the most dominating region in the anti-infectives market and is followed by Europe. The emerging economies of Asia-Pacific regions are also showing growth potential in the global anti-infectives market. India forecasts high potential for growth in demand for anti-infectives due to existence of large patient pool, the government initiatives of undertaking various control programs and private partnership projects and rising cost containment initiatives by drug manufacturers.

Some of the major driving factors for the anti-infectives market include increase in patient population, large number of vaccines gaining approvals and newer drug introductions. The growing resistance of infection causing organisms to the existing drug therapies could pose a major challenge to the anti-infectives market. Furthermore, high price of drugs, dicey reimbursement policies and competition between generic manufacturers may hold back the growth of this market. The anti-infectives market is highly fragmented with a large number of domestic and international players. Developmental focus of anti-infective agents has shifted to antiviral agents due to requirement of longer treatment regimens in large number of patient population with chronic indications as compared to antifungal and antibacterial agents requiring shorter treatments.

Some of the key players contributing to the growth of this market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Panacea Biotech Ltd., Pfizer Ltd., Ranbaxy Laboratories Ltd. and Sun Pharmaceutical Industries Ltd.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
All new upcoming reports: http://www.transparencymarketresearch.com/latest.php?type=U

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.